Postoperative venous thromboembolism predicts survival in cancer patients

Annals of Surgery

Volumn 255, Issue 5, 2012, Pages 963-970

  Auer, Rebecca Ann C ^a   Scheer, Adena Sarah ^a   McSparron, Jakob I ^c   Schulman, Allison R ^c   Tuorto, Scott ^c   Doucette, Steve ^b   Gonsalves, Jamie ^c   Fong, Yuman ^c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL SURGERY; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DATA BASE; DEEP VEIN THROMBOSIS; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LAPAROSCOPY; LAPAROTOMY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PELVIS SURGERY; POSTOPERATIVE PERIOD; PRIMARY TUMOR; PRIORITY JOURNAL; THORACOSCOPY; THORACOTOMY; THORAX SURGERY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GASTROINTESTINAL NEOPLASMS; GENITAL NEOPLASMS, FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SKIN NEOPLASMS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84859910458     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31824daccb     Document Type: Conference Paper

References (59)

1. Lyman GH, Khorana AK. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009;27:4821-4826.
2. Heit JA, SilversteinMD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med. 2000;160:809-815. (Pubitemid 30165241)
3. Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am. 1996;10:499-530. (Pubitemid 26097349)
4. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol. 2001;106:6-12. (Pubitemid 32830510)
5. Falanga A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis. 1998;28(suppl 3):50-60. (Pubitemid 29049321)
6. Blom JW, Doggen CJM, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715-722. (Pubitemid 40216041)
7. Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128-1133.
8. Nierodzik M, Karpathkin S. Hypercoagulability preceding cancer: does hypercoagulability awaken dormant tumor cells in the host? J Thromb Haemost. 2005;3:577-580.
9. Baron JA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer. Lancet. 1998;351:1077-1080. (Pubitemid 28163410)
10. Sørensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338:1169-1173. (Pubitemid 28180744)
11. Carrier M, Le Gal G, Wells PS, et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152:578-589.
12. Stein PD, Beemath A,Meyers FA, et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119:60-68. (Pubitemid 43117468)
13. Zakai NA, Wright J, Cushman M: Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost. 2004;2:2156-2161. (Pubitemid 40185776)
14. Prins M, Otten H-MM. Thrombosis and cancer. A short history of Trousseau's syndrome. In: Lugassy G, Falanga A, Kakkar A, Rickles F, eds. Thrombosis and Cancer. London, England: Taylor and Francis; 2004:1-10.
15. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors. Determination of frequency and characteristics. Thromb Haemost. 2002;87:575-579. (Pubitemid 34302943)
16. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Med (Baltimore). 1999;78:285-291. (Pubitemid 29439263)
17. Sørensen HT, Mellemkjaer L, Osen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-1850. (Pubitemid 32104130)
18. Chew HK, Wun T, Harvey DJ, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458-464.
19. Chew HK, Wun T, Harvey DJ, et al. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol. 2007;25: 70-76. (Pubitemid 350003053)
20. Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Onc. 2006;24:1112-1118. (Pubitemid 46638808)
21. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23)(suppl 1):I9-I16. (Pubitemid 41289266)
22. Auer RA, et al. Use of helical CT is associated with an increased incidence of postoperative pulmonary emboli in cancer patients with no change in the number of fatal pulmonary emboli. J Am Coll Surg. 2009;208:871-878; discussion 878-880.
23. Chew HK, Davies AM, Wun T, et al. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008;6:601-608 (Pubitemid 351404927)
24. Mason DP, Quader MA, Blackstone EH, et al. Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome. J Thorac Cardiovasc Surg. 2006;131:711-718.
25. Khorana. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125:490-493.
26. Shigemori C, Wada H, Matsumot K, et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost. 1998;80:894-898. (Pubitemid 28556688)
27. Seto S, Onodera H, Kaido T, et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer. 2000;88:295-301. (Pubitemid 30051812)
28. Mueller BM, Reisfeld RA, Edgington TS, et al. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA. 1992;89:11832-11836. (Pubitemid 23004738)
29. NadirY,BrennerB.Heparanse procoagulant effects and inhibition by heparins. Thromb Res. 2010;125:S72-S76.
30. Sierko E,Wojtkiewicz MZ. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin ThrombHemost. 2007;33:712-721. (Pubitemid 350157017)
31. HejnaM, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst. 1999;91:22-36. (Pubitemid 29042440)
32. Gasic GJ, Gasic TB, Galanti N, et al. Platelet-tumor-cell interactions in mice: the role of platelets in the spread of malignant disease. Int J Cancer. 1973;11:704-718.
33. GasicGJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA. 1968;61:46-52.
34. Taucher S, Salat A, Gnant M, et al. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost. 2003;89:1098-1106. (Pubitemid 36798163)
35. Kandemir EG, Mayadagli A, Karagoz B, et al. Prognostic significance of thrombocytosis in node-negative colon cancer. J Int Med Res. 2005;33:228-235. (Pubitemid 40372439)
36. Palumbo JS, Potter JM, Kaplan LS, et al. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 2002;62:6966-6972. (Pubitemid 35424088)
37. Dvorak HF, Nagy JA, Berse B, et al. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation.AnnNYAcad Sci. 1992;667:101-111. (Pubitemid 23061569)
38. Dejana E, Languino LR, Polentarutti N, et al. Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. J Clin Invest. 1985;75:11-18. (Pubitemid 15163960)
39. Dvorak HF, Harvey VS, Estrella P, et al. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest. 1987;57:673-686. (Pubitemid 18031786)
40. Auer RA, SethR,MacKenzie L, et al. Surgical stress promotes the development of metastatic disease by a coagulation-dependent mechanism. Thromb Hemost. 2010;125:S170-S171.
41. Boccaccio C, Comoglio PM. Genetic link between cancer and thrombosis. J Clin Oncol. 2009;27:4827-4833.
42. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol. 2009;27:4834-4838.
43. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem. 2000;275:1521-1524. (Pubitemid 30060762)
44. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin and cancer. Chest. 2003;124:58S-68S.
45. Palumbo JS, Mullins ES, Degen JL. Genetic analysis of hemostatic factors and cancer. In: Khorana A, Francis C, eds. Cancer-Associated Thrombosis. New York, NY. Informa Healthcare, 2008:51-63.
46. Palumbo JS, Talmage KE, Liu H, et al. Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency. Blood. 2003;102:2819-2827. (Pubitemid 37248852)
47. Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105:178-185. (Pubitemid 40053080)
48. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous lowmolecular-weight heparin with intravenous standard heparin in proximal deepvein thrombosis. Lancet. 1992;339:441-445.
49. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost. 1999;82:947-952.
50. Lee AY, Levine MN, Baker RI, et al. Low molecular weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153. (Pubitemid 36818784)
51. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23:2123-2129. (Pubitemid 46218703)
52. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130-2135. (Pubitemid 46218704)
53. Kakkar AK, Levine M, Kadziola Z, et al. Low molecular weight heparin therapy with dalteparin and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004:22: 1944-1948. (Pubitemid 41095187)
54. Altinabas M, Coskun HS, Er O, et al. Randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;2:1266-1271. (Pubitemid 40186120)
55. Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase III clinical trial. Mayo Clin Proc. 2006;81:758-767. (Pubitemid 43839491)
56. von Tempelhoff GF, Harenberg J, Niemann F, et al. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized doubleblind trial. Int J Oncol. 2000;16:815-824.
57. Lazo-Langner A, Goss GD, Spaans JN, et al. The effect of low-molecularweight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost. 2007;5:729-737. (Pubitemid 46563571)
58. Mandala M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. AnnOncol. 2007;18:1660-1665. (Pubitemid 47506252)
59. Gross CP, Galusha DH, Krumholz HM. The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients. J Gen Intern Med. 2007;22:321-326. (Pubitemid 46941220)